Current status and use of short/medium term models for carcinogenicity testing of pharmaceuticals - Scientific perspective

Toxicology Letters

Volumn 112-113, Issue , 2000, Pages 557-566

  Storer, Richard D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Carcinogenicity; Neonatal mouse; Short term; Testing; Transgenics

Indexed keywords

CARCINOGEN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHYLNITROSOUREA; NEW DRUG; PROTEIN P53; RAS PROTEIN;

ANIMAL MODEL; BIOASSAY; CARCINOGEN TESTING; CARCINOGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; DATA BASE; DRUG RESEARCH; DRUG SCREENING; GENE ACTIVATION; MODEL; MOUSE; NEWBORN; NONHUMAN; ONCOGENE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; TECHNIQUE; TRANSGENE; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; XERODERMA PIGMENTOSUM;

ANIMALS; ANIMALS, NEWBORN; BIOLOGICAL ASSAY; CARCINOGENICITY TESTS; DISEASE MODELS, ANIMAL; DRUG INDUSTRY; MICE; MICE, TRANSGENIC; MODELS, GENETIC; NEOPLASMS, EXPERIMENTAL;

MUS MUSCULUS; RODENTIA;

EID: 0034654038     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(99)00227-1     Document Type: Conference Paper

References (53)

1. Ando K., Saitoh A., Hino O., Takahashi R., Kimura M., Katsuki M. Chemically-induced forestomach papillomas in transgenic mice carry mutant human c-Ha-ras transgenes. Cancer Res. 52:1992;978-982.
2. Cannon R.E., Spaulding J.W., Trempus C.S., Szczesniak C.J., Virgil K.M., Humble M.C., Tennant R.W. Kinetics of wound induced v-Ha-ras transgene expression and papilloma development in transgenic Tg.AC mice. Mol. Carcinog. 20:1997;108-114.
3. Cannon R.E., Spaulding J.W., Virgil K.M., Faircloth R.S., Humble M.C., Lacks G.D., Tennant R.W. Induction of transgene expression in Tg.AC (v-Ha-ras) transgenic mice concomitant with DNA hypomethylation. Mol. Carcinog. 21:1998;244-250.
4. Cardiff R.D., Leder A., Kuo A., Pattengale P.K., Leder P. Multiple tumor types appear in a transgenic mouse with the ras oncogene. Am. J. Pathol. 142:1993;1199-1207.
5. Contrera J.F., DeGeorge J.J. In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals. Environ. Health Perspect. 106(Suppl. 1):1998;71-80.
6. de Vries A., van Steeg H. Xpa knockout mice. Semin. Cancer Biol. 7:1996;229-240.
7. de Vries A., van Oostrom C.T.M., Hofhius F.M.A., Dortant P.M., Berg F.J.W., de Gruijl F.R., Wester P.W., van Kreijl C.F., Capel P.J.A., van Steeg H., Verbeek S.J. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature. 377:1995;169-173.
8. de Vries A., Dolle M.E., Broekhof J.L., Muller J.J., Kroese E.D., van Kreijl C.F., Capel P.H., Vijg J., van Steeg H. Induction of DNA adducts and mutations in spleen, liver and lung of XPA-deficient/lacZ transgenic mice after oral treatment with benzo[a]pyrene: correlation with tumour development. Carcinogenesis. 18:1997;2327-2332.
9. de Vries A., van Oostrom C.T., Dortant P.M., Beems R.B., van Kreijl C.F., Capel P.J., van Steeg H. Spontaneous liver tumors and benzo[a]pyrene-induced lymphomas in XPA-deficient mice. Mol. Carcinog. 19:1997;46-53.
10. Donehower L.A. The p53-deficient mouse: a model for basic and applied cancer studies. Semin. Cancer Biol. 7:1996;269-278.
11. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A. Jr, Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature. 356:1992;215-221.
12. Donehower L.A., Harvey M., Vogel H., McArthur M.J., Montgomery C.A. Jr, Park S.H., Thompson T., Ford R.J., Bradley A. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol. Carcinog. 14:1995;16-22.
13. Dunnick J.K., Hardisty J.F., Herbert R.A., Seely J.C., Furedi-Machacek E.M., Foley J.F., Lacks G.D., Stasiewicz S., French J.E. Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (+/-) mice. Toxicol. Pathol. 25:1997;533-540.
14. Flammang T.J., VonTungeln L.S., Kadlubar F.F., Fu P.P. Neonatal mouse assay for tumorigenicity. Regul. Toxicol. Pharmacol. 26:1997;230-240.
15. Fuji K. Evaluation of the newborn mouse model for chemical tumorigenesis. Carcinogenesis. 12:1991;1409-1415.
16. Goodrow T.L., Storer R.D., leander K.R., Prahalada S.R., van Zwieten M.J., Bradley M.O. Murine p53 intron sequences 5-8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CD-1 mouse liver and lung tumors. Mol. Carcinog. 5:1992;9-15.
17. Graves S., Cannon R.E., Spaulding J.W., Furedi-Machacek E.M., Tice R.R., Tennant R.W. Oral administration of DMVC in TG.AC mice induces v-Ha-ras transgene expression in forestomach. Environ. Mol. Mutagen. 29:1997;18.
18. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
19. Hansen L., Tennant R. Focal transgene expression associated with papilloma development in v-Ha-ras transgenic TG.AC mouse skin. Mol. Carcinog. 9:1994;143-154.
20. Hansen L., Spaulding J.W., French J.E., Tennant R.W. A transgenic mouse model (Tg.AC) for skin tumorigeneis: Inducible transgene expression as a second critical event. Slaga T. Growth Factors and Tumor Promotion: Implications for Risk Assessment. 1994;223-235 Wiley-Liss, New York.
21. Harvey M., McArthur M.J., Montgomery C.A. Jr, Butel J.S., Bradley A., Donehower L.A. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet. 5:1993;225-229.
22. Harvey M., Vogel H., Morris D., Bradley A., Bernstein A., Donehower L.A. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet. 9:1995;305-311.
23. International Conference on Harmonisation, 1998. Guidance on testing for carcinogenicity of pharmaceuticals. Fed. Reg. 63:8983-8986.
24. Kelly W.A., Nelson L.W., Hawkins H.C., Weikel J.H. J.R. An evaluation of the tumorigenicity of cyclophosphamide and urethan in newborn mice. Toxicol. Appl. Pharmacol. 27:1974;629-640.
25. Kemp C.J., Wheldon T., Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat. Genet. 8:1994;66-69.
26. Leder A., Kuo A., Cardiff R.D., Sinn E., Leder P. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA. 87:1990;9178-9182.
27. Manam S., Storer R.D., Prahalada S., Leander K.R., Kraynak A.R., Hammermeister C.L., Joslyn D.J., Ledwith B.J., van Zwieten M.J., Bradley M.O., Nichols W.W. Activation of the Ki-ras gene in spontaneous and chemically-induced lung tumors in CD-1 mice. Mol. Carcinog. 6:1992;68-75.
28. Manam S., Storer R.D., Prahalada S., Leander K.R., Kraynak A.K., Ledwith B.J., van Zwieten M.J., Bradley M.O., Nichols W.W. Activation of the Ha-, Ki-, and N-ras genes in chemically induced liver tumors from CD-1 mice. Cancer Res. 52:1992;3347-3352.
29. Mitsumori K., Wakana S., Yamamoto S., Kodama Y., Yasuhara K., Nomura T., Hayashi Y., Maranpot R.R. Susceptibility of transgenic mice carrying human prototype c-Ha-ras gene in a short-term carcinogenicity study of vinyl carbamate and ras gene analyses on the induced tumors. Mol. Carcinog. 20:1997;298-307.
30. Mitsumori K., Koizzumi H., Nomura T., Yamamoto S. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. Toxicol. Pathol. 26:1998;520-531.
31. Ozaki K., Sukata T., Yamamoto S., Uwagawa S., Seki T., Kawaski H., Yoshitake A., Wanibuchi H., Koide A., Mori Y., Fukushima S. High susceptibility of p53(+/-) knockout mice in n-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res. 58:1998;3806-3811.
32. Pattengale P.K., Stewart T.A., Leder A., Sinn E., Muller W., Tepler I., Schmidt E., Leder P. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes. Am. J. Pathol. 135:1989;39.
33. Robinson D. The International Life Science Institute's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk. Toxicol. Pathol. 26:1998;474-475.
34. Sagartz J.E., Curtiss S.W., Bunch R.T., Davila J.C., Morris D.L., Alden C.L. Phenobarbital does not promote hepatic tumorigenesis in a twenty-six-week bioassay in p53 heterozygous mice. Toxicol. Pathol. 26:1998;492-500.
35. Saitoh A., Kimura M., Takahashi R., Yokoyama M., Nomua T., Izawa M., Sekiya T., Nishimura S., Katsuki M. Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene. 5:1990;1195-1200.
36. Schwetz B., Gaylor D. Alternative tests: carcinogenesis as an example. Environ. Health Perspect. 106(Suppl. 2):1998;467-471.
37. Spaulding J.W., Momma J., Elwell M.R., Tennant R.W. Chemically-induced skin carcinogenesis in a transgenic mouse line (Tg.AC) carrying a v-Ha-ras gene. Carcinogenesis. 14:1993;1335-1341.
38. Spaulding, J.W., French, J.E., Tice, R.R., Furedi-Machachek, M., Haseman, J.K., Tennant, R.W., 1999. Transgenic models for chemcial carcinogenesis bioassays. Chemically-induced skin tumors in TG.AC mice: data base for protocol development. Fundam. Appl. Toxicol. 49: 241-254.
39. Tennant R.W. Evaluation and validation issues in the development of transgenic mouse carcinogenicity bioassays. Environ. Health Perspect. 106(Suppl. 2):1998;473-476.
40. Tennant R.W., French J.E., Spalding J.W. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect. 103:1995;942-950.
41. Tennant R.W., Spalding J., French J.E. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat. Res. 365:1996;119-127.
42. Tennant, R.W., Stasiewicz, S., Mennear, J., French, J.E., Spalding, J.W., 1999. Genetically altered mouse models for carcinogen identification. In: McGregor, D., Rice, J., Venitt, S. (Eds.), Results of Short- and Medium-Term Tests for Carcinogens and Data on Genetic and Related Effects in Carcinogen Hazard Evaluations. IARC Scientific Publications 146, 123-150.
43. Thompson K.I., Rosenzweig B.A., Sistare F.D. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness. Toxicol. Pathol. 26:1998;548-555.
44. Trempus C.S., Ward S., Farris G., Malarkey D., Faircloth R.S., Cannon R.E., Mathler J.F. Association of v-Ha-ras transgene expression with development of erytholeukemia in TG.AC transgenic mice. Am. J. Pathol. 153:1998;247-254.
45. van Oostrom C.T.M., de Vries A., Verbeek S.J., van Kreijl C.F., van Steeg H. Cloning and characterization of the mouse XPAC gene. Nucleic Acids Res. 22:1994;11-14.
46. van Steeg H., Klein H., Beems R., van Kreijl C.F. Use of DNA repair-deficient XPA transgenic mice in short-term carcinogenicity testing. Toxicol. Pathol. 26:1998;742-749.
47. Venkatachalam S., Shi Y.-P., Jones S.N., Vogel H., Bradley A., Pinkel D., Donehower L.A. Retention of wild type p53 in tumors from p53 heterozygous mice: reduction of p53 gene dosage can promote cancer formation. EMBO J. 17(16):1998;4657-4667.
48. Weaver J.L., Contrera J.F., Rosenzweig B.A., Thompson K.L., Faustino P.J., Strong J.M., Ellison C.D., Anderson L.W., Prasanna H.R., Long-Bradley P.E., Lin K.K., Zhang J., Sistare F.D. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. I. Evidence for a confounding nonresponder phenotype. Toxicol. Pathol. 26:1998;532-540.
49. Wright J.T., Hansen L., Mahler J., Szczesniak C., Spalding J.W. Odontogenic tumours in the v-Ha-ras (Tg.AG) transgenic mouse. Arch. Oral Biol. 40:1995;631-638.
50. Yamamoto S., Mitsumori K., Kodama Y., Matsunuma N., Manabe S., Okamiya H., Suzuki H., Fukuda T., Sakamaki Y., Sunaga M., Nomura G., Hioki K., Wakana S., Nomura T., Hayashi Y. Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice. Carcinogenesis. 17:1996;2455-2461.
51. Yamamoto S., Mitsumori K., Hayashi Y., Nomura T. Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-Ha-ras gene. Lab. Anim. Sci. 47:1997;121-126.
52. Yamamoto S., Urano K., Koizumi H., Wakana S., Hioki K., Mitsumori K., Kurokawa Y., Hayashi Y. Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Environ. Health Perspect. 106(Suppl. 1):1998;57-69.
53. Yamamoto S., Urano K., Nomura T. Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Toxicol. Lett. 102-103:1998;473-478.